Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eicosanoids and the liver.

S Sinclair1, G Levy

  • 1Department of Medicine, University of Toronto, Canada.

The Italian Journal of Gastroenterology
|August 1, 1990
PubMed
Summary
This summary is machine-generated.

Prostaglandins (PG) and leukotrienes are key mediators in liver function and disease. Research shows PG compounds like PGE2 offer protection against liver injury and are used to treat viral hepatitis, improving patient survival rates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monoclonal antiprothrombinase (3D4.3) prevents mortality from murine hepatitis virus (MHV-3) infection.

The Journal of experimental medicine·1992
Same author

From front line to home front: a study of secondary traumatization.

Family process·1992
Same author

Publication bias: its implications for clinical pharmacology.

Clinical pharmacology and therapeutics·1992
Same author

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.

Journal of pharmaceutical sciences·1992
Same author

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.

Pharmaceutical research·1992
Same author

Comparison of functional activity in host and graft mesenteric lymphoid tissue of rats receiving syngeneic heterotopic small bowel allografts with portal or systemic drainage.

Transplantation proceedings·1992
Same journal

Recent Advances on NSAID and NSAID Gastropathy, 1st annual meeting. Ferrara, Italy, 6-7 December 1996. Proceedings.

The Italian journal of gastroenterology·1996
Same journal

Irritable oesophagus syndrome as cause of chronic cough.

The Italian journal of gastroenterology·1996
Same journal

Small bowel tumours in Tuscany.

The Italian journal of gastroenterology·1996
Same journal

Prevalence of hepatitis E in a central Italian town at high endemicity for hepatitis C virus.

The Italian journal of gastroenterology·1996
Same journal

Stimulatory effect of (R) alpha-methylhistamine on duodenal HCO3- secretion in anaesthetized rats.

The Italian journal of gastroenterology·1996
Same journal

Delayed gastric emptying in an infant with Sandifer syndrome.

The Italian journal of gastroenterology·1996
See all related articles

Area of Science:

  • Hepatology
  • Immunology
  • Pharmacology

Background:

  • Prostaglandins (PG) and leukotrienes are crucial mediators in liver physiology and disease.
  • While their metabolic pathways are known, cellular mechanisms of action require further elucidation.
  • Existing research highlights leukotrienes in liver injury pathogenesis and PG's protective roles in animal models.

Purpose of the Study:

  • To review the role of prostaglandins and leukotrienes in liver function and disease.
  • To explore the therapeutic potential of prostaglandins in treating liver conditions.

Main Methods:

  • Review of experimental animal models of liver injury (ischemia, galactosamine, CCl4, LPS).
  • Analysis of studies investigating prostaglandin E2 (dm PGE2) in viral hepatitis models.

Related Experiment Videos

  • Examination of clinical data on prostaglandin E1 (PGE1) use in fulminant viral hepatitis and post-transplant settings.

    • Main Results:

    • Prostaglandins demonstrate protective effects in various experimental liver injury models.
    • 16,16 dimethyl PGE2 (dm PGE2) showed protective properties in a mouse viral hepatitis model.
    • Intravenous PGE1 improved survival in fulminant viral hepatitis and was used for primary non-function and recurrent hepatitis B post-transplantation.

    Conclusions:

    • Prostaglandins exhibit significant hepatoprotective mechanisms, including abrogating inflammatory mediators and potentially inhibiting viral replication.
    • Prostaglandins play a role in renal dysfunction associated with cirrhosis and fulminant hepatic failure.
    • Further research into prostaglandins for liver disease treatment and complication management is warranted.